Thrombin generation test in patients under anticoagulant therapy with vitamin k antagonists

Isabel Brocal; Pascual Marco; Javier Lucas; José Verdú; Fabián Tarín

doi:10.1160/TH08-07-0465

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2009; 101(03): 594-595
DOI: 10.1160/TH08-07-0465

Letters to the Editor

Schattauer GmbH

Thrombin generation test in patients under anticoagulant therapy with vitamin k antagonists

Isabel Brocal

¹Thrombosis and Haemostasis Unit, University General Hospital of Alicante, Alicante, Spain

,

Pascual Marco

¹Thrombosis and Haemostasis Unit, University General Hospital of Alicante, Alicante, Spain

,

Javier Lucas

¹Thrombosis and Haemostasis Unit, University General Hospital of Alicante, Alicante, Spain

,

José Verdú

¹Thrombosis and Haemostasis Unit, University General Hospital of Alicante, Alicante, Spain

,

Fabián Tarín

¹Thrombosis and Haemostasis Unit, University General Hospital of Alicante, Alicante, Spain

› Author Affiliations

Abstract

Full Text

References

References
1 Lassen JF, Kjeldsen J, Antonsen S. et al. Interpretation of serial measurements of international normalized ratio for prothrombin times in monitoring oral anticoagulant therapy. Clin Chem 1995; 41: 1171-1176.
2 Hemker HC, Al Dieri R, De Smedt E. et al. Thrombin generation, a function test of the haemostaticthrombotic system. Thromb Haemost 2006; 96: 553-561.
3 Gatt A, van Veen JJ, Woolley AM. et al. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro. Thromb Haemost 2008; 100: 350-355.
4 Dempfle CE, Borggrefe M. Do we need thrombin generation assays for monitoring anticoagulation?. Thromb Haemost 2008; 100: 179-180.
5 Gerotziafas GT, Depasse F, Busson J. et al. Towards a standardization of thrombin generation assessment: the influence of tissue factor, platelets and phospholipids concentration on the normal values of Thrombogram-Thrombinoscope assay. Thromb J 2005; 3: 16.
6 Wielders S, Mukherjee M, Michiels J. et al. The routine determination of the endogenous thrombin potential, first results in different forms of hyper- and hypocoagulability. Thromb Haemost 1997; 77: 629-636.
7 Altman R, Scazziota A, Herrera L. et al. Relationship between thrombin generation and international normalized ratio in patients receiving oral vitamin K antagonist therapy. J Thromb Haemost 2007; 5: 1552-1569.
8 Chantarangkul VCM, Bressi C, Giesen P. et al. Thrombin generation assessed as endogenous thrombin potential in patients with hyper- or hypocoagulability. Haematologica 2003; 88: 547-554.
9 ten Cate-Hoek AJ, Dielis AW, Spronk HM. et al. Thrombin generation in patients after acute deep-vein thrombosis. Thromb Haemost 2008; 100: 240-245.
10 Hron G, Kollars M, Binder BR. et al. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. J Am Med Assoc 2006; 296: 397-402.
11 Besser M, Baglin C, Luddington R. et al. High rate of unprovoked recurrent venous thrombosis is associated with a high thrombin generating potential in a prospective cohort study. J Thromb Haemost 2008; 6: 1720-1725.
12 Orbe J, Zudaire M, Serrano R. et al. Increased thrombin generation after acute versus chronic coronary disease as assessed by the thrombin generation test. Thromb Haemost 2008; 99: 382-387.